2019 ACR/ARP Annual Meeting*

November 8-13, 2019; Atlanta, Georgia
Review the latest RA management data with Capsule Summaries and expert-authored commentaries covering key studies from ACR 2019.

Rheumatoid Arthritis Highlights From ACR 2019

Capsule Summary Slidesets

Results of this pooled analysis of 3 randomized, controlled phase III trials show filgotinib to be well tolerated, with no new safety signals, and low rates of MACE/VTE.

Released: November 18, 2019

Retrospective cohort suggests HCQ did not protect against MACE among patients initiating treatment within the prior year but did reduce risk of all-cause mortality.

Released: November 18, 2019

Meta-analysis of 33 randomized, placebo-controlled trials identified no increased short-term risks for MACE or VTE.

Released: November 18, 2019

Similar disease flare rates with both tapering schedules, but tapering csDMARD first associated with numerically higher DMARD-free remission.

Released: November 15, 2019

PF-06650833 associated with improvements in SDAI in primary analysis.

Released: November 18, 2019

Mode of action appears to be in normalization of key downstream pathways of the pathobiology of RA, including lymphocyte and myeloid cell pathways.

Released: November 13, 2019

Analysis of pooled data from 5 phase III RCTs in RA patients suggests that upadacitinib causes no apparent increase in MACE or VTE over 24 months.

Released: November 14, 2019

Baricitinib safety through 7 years acceptable and similar to that previously reported.

Released: November 25, 2019

Positive data from this small 14-patient study support broader investigation of vagus nerve stimulation as a novel therapeutic modality in patients with RA in whom biologics or targeted oral therapies have failed.

Released: November 15, 2019

Noninferiority of ultralow-dose rituximab for the treatment of RA could not be established by this protocol

Released: November 15, 2019
Provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
Gilead Sciences
Mallinckrodt Pharmaceuticals

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue